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Article

Tryptophan hydroxylase-1 regulates immune
tolerance and inflammation
Elizabeth C. Nowak,1 Victor C. de Vries,1 Anna Wasiuk,1 Cory Ahonen,1
Kathryn A. Bennett,1 Isabelle Le Mercier,1 Dae-Gon Ha,1
and Randolph J. Noelle1,2
of Microbiology and Immunology, Dartmouth Medical School and the Norris Cotton Cancer Center,
Lebanon, NH 03756
2Medical Research Council Centre for Transplantation, Guy’s Hospital, King’s College London, King’s Health Partners,
London SE1 9RT, England, UK
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Nutrient deprivation based on the loss of essential amino acids by catabolic enzymes in the
microenvironment is a critical means to control inflammatory responses and immune tolerance.
Here we report the novel finding that Tph-1 (tryptophan hydroxylase-1), a synthase which
catalyses the conversion of tryptophan to serotonin and exhausts tryptophan, is a potent
regulator of immunity. In models of skin allograft tolerance, tumor growth, and experimental
autoimmune encephalomyelitis, Tph-1 deficiency breaks allograft tolerance, induces tumor
remission, and intensifies neuroinflammation, respectively. All of these effects of Tph-1
deficiency are independent of its downstream product serotonin. Because mast cells (MCs)
appear to be the major source of Tph-1 and restoration of Tph-1 in the MC compartment
in vivo compensates for the defect, these experiments introduce a fundamentally new mechanism of MC-mediated immune suppression that broadly impacts multiple arms of immunity.
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One well-documented method to control immunity and tolerance is through the regulation
of nutrients in their immune microenvironment.
Best described is the tryptophan deficiency
mediated by the catabolic enzyme indoleamine
2,3-dioxygenase (IDO), which locally depletes
tryptophan and liberates the immunoregulatory
metabolites known as kynurenines. T cell activation is exquisitely sensitive to local tryptophan
catabolism, and thus this enzyme exerts profound
protective effects in allo-fetal rejection, auto
immunity, and inflammation. IDO can also be
detected in tumors and draining LNs, and DC
expression of IDO limits T cell responsiveness to
antigen (Munn and Mellor, 2007; Katz et al.,
2008). In addition to IDO, some human cancers
express tryptophan 2,3-dioxygenase (TDO),
which also utilizes tryptophan as a substrate to
produce kynurenines (Pilotte et al., 2012). Furthermore, cysteine and arginine deficiency in
tumors can inhibit T cell activation (Rodriguez
et al., 2004; Srivastava et al., 2010), suggesting
that loss of any number of amino acids may
serve as a common tumor escape mechanism.
E.C. Nowak, V.C. de Vries, and A. Wasiuk contributed
equally to this paper.
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In accordance with these findings, in a model
of skin allograft tolerance, it was observed that
multiple catabolic enzymes were up-regulated
that consume a litany of essential amino acids.
It was shown that these enzymatic activities could
dampen T cell proliferation through nutrient
deprivation (Cobbold et al., 2009). One of the
many enzymes that were up-regulated was
Tph-1 (tryptophan hydroxylase-1), a synthase
which utilizes tryptophan as a substrate to produce serotonin and melatonin (Yao et al., 2011),
and it was speculated that Tph-1 may precipitate the loss of tryptophan in the local micro
environment (Zelenika et al., 2001). In the
present study, we sought to determine whether
Tph-1, the isoform expressed in the periphery
(Walther et al., 2003), could function as a
regulator of immunity through the control of
tryptophan metabolism and uncovered a novel
and profound immunoregulatory function for
this enzyme.
© 2012 Nowak et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after
the publication date (see http://www.rupress.org/terms). After six months it is
available under a Creative Commons License (Attribution–Noncommercial–Share
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Figure 1. MCs have specific expression of Tph-1. (A) Tph-1 expression (as determined by qRT-PCR) of the indicated cell types standardized
to -actin expression (mean ± SEM) is shown. For each cell type, two independent FACS-sorted samples were used. Each MC and macrophage sample
was pooled from the peritoneal lavage of 20 mice. All other samples were pooled from the LN and spleen of two to four mice. (B) Peritoneal MC expression of the following genes was determined by qRT-PCR: arginase (Arg), dopa decarboxylase (Ddc), histidine decarboxylase (Hdc), IDO, inducible nitric oxide
synthase (iNos), l-threonine dehydrogenase (Tdh), TDO, Tph-1, and Tph-2. Two independent samples were used to determine mean ± SEM shown.
(A and B) ND indicates that a signal was not detected. (C) Intracellular staining for Tph-1 was performed for MCs, CD4+ T cells, CD8+ T cells, B cells,
CD11chi DCs, and F4/80+ CD11b+ macrophages in WT (bold lines) and Tph-1/ (shaded areas) mice (n = 3–4 mice/group, and each cell type was tested in
at least two independent experiments). (D) Naive LN sections were sectioned and stained for Tph-1 expression on MCs. CD117 staining is blue, Tph-1
staining is green, and overlap is white. Results are representative of three different mice/group. Bar, 10 µm.

RESULTS
Mast cells (MCs) express Tph-1
A study from our laboratory previously reported that MCs
are critical in maintaining regulatory T cell–dependent skin
allograft tolerance (Lu et al., 2006). Concordant with these
observations, gene array analyses performed by two different groups established that tolerant skin allografts display
an MC signature with heightened signal for Tph-1 and
other MC gene products (Zelenika et al., 2001; Lu et al.,
2006). Pilot experiments showed that purified MCs from
tolerant allografts expressed heightened levels of Tph-1
compared with MCs from syngeneic grafts (not depicted).
It was also observed that peritoneal MCs from naive mice
express 1,000-fold higher expression for Tph-1 message
than any other hematopoietic cell type examined by quantitative RT-PCR (qRT-PCR) and that Tph protein
expression appears to be restricted to MCs (Fig. 1). Heightened Tph-1 expression in MCs appeared unique, as the
expression for other catabolic enzymes was absent or minimal (Fig. 1 B).
2128

Figure 2. Tph-1/ mice have elevated serum tryptophan levels
and a normal MC compartment. (A) Serum tryptophan levels from
in-house-bred naive WT and Tph-1/ mice (n = 13–14 mice/group from
three independent experiments) were determined by ELISA. Mean ± SEM
is shown. The p-value was determined by Student’s t test. (B) Peritoneal
lavage, lungs, intestines, spleen, and skin of Tph-1/ mice were analyzed
by flow cytometry for the relative number of MCs and compared with WT
mice. Data are pooled from two independent experiments (n = 7–8 mice/
group), and mean is indicated.
Tph-1 regulation of immunity | Nowak et al.
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Based on these findings and the recognition that Tph-1
can locally deplete tryptophan, the potential functional involvement of Tph-1 in mediating immune tolerance within
the skin microenvironment was studied in Tph-1/ mice.
Tph-1/ mice have been previously described as harboring no gross physical abnormalities except diminished cardiac
function (Côté et al., 2003) and enhanced liver microcirculation (Lang et al., 2008). However, the immune compartments of Tph-1/ mice have not been well characterized.
The genetic absence of Tph-1 appears to impact the steadystate levels of tryptophan as serum from Tph-1/ mice
contains 5 µg/ml more tryptophan in serum than that of
WT controls (P = 0.0152; Fig. 2 A). Although systemic

levels of tryptophan are generally attributed to the activ
ity of TDO, it appears that IDO can modulate the relative
amounts of tryptophan under inflammatory conditions
(Schröcksnadel et al., 2006). Therefore, it appears that constitutive loss of Tph-1 can also alter tryptophan levels in the
periphery. The analysis of immune cell phenotypes on WT
and Tph-1/ mice revealed that these mice were indistinguishable across all tissues examined (not depicted). Furthermore, the lack of Tph-1 does not appear to impact the
frequency (Fig. 2 B) or numbers (not depicted) of MCs,
which have been described as the cells most abundantly
expressing Tph-1 (Stoll et al., 1990; Mathiau et al., 1994;
Csaba et al., 2006).

Figure 3. Tph-1 is essential for the maintenance of tolerance. (A and B) WT and Tph-1/ mice were grafted with syngeneic C57BL/6 or allogeneic
CB6F1 skin. DST- and -CD40L–treated mice received an allogeneic skin graft. In the indicated groups, PCPA and 5-HTP were given every other day for the
duration of the experiment starting at day 8 for DST/-CD40L–treated mice and day 1 for syngeneic and allogeneic mice. The number of mice/group
is indicated, and data were pooled from two or more independent experiments. (C) Histology staining on skin allografts in DST/-CD40L–treated mice
of Tph-1 or WT mice at day 10 after grafting. Tph-1 is shown in red, and cKit (CD117) is shown in blue. In the overlay, white arrows indicated doublepositive cells, and blue arrows indicate cells positive for cKit but not for Tph-1. (D) Reconstitution of serotonin in the granules of MCs was confirmed by
immunofluorescent staining on purified peritoneal lavage MCs. Serotonin staining is in red, cKit staining in blue, and nuclear staining in yellow. The
white arrows indicate MCs positive for serotonin, whereas the red arrows indicate MCs negative for serotonin. Bars, 20 µm. (E) Graft draining LNs from
DST/-CD40L–treated mice were depleted of antigen-presenting cells and restimulated with irradiated WT of F1 antigen-presenting cells for 18 h for IFN-
and for 36 h for IL-17A before ELISPOT development. Data show n = 7–8 mice/group, and mean ± SEM is representative of results from two independent
experiments. P-values were determined by Student’s t test. (F) Mast-deficient (Wsh) mice were locally (skin) reconstituted with 6–8-wk-old MCs from WT
or Tph-1/ mice 8 wk before DST/-CD40L treatment. After receiving a skin graft, mice were monitored for rejection for another 50 d. Data shown were
combined from two independent experiments.
JEM Vol. 209, No. 11
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Donor-specific transfusion (DST)/-CD40L–treated mice
reject allogeneic skin grafts with Tph-1 deficiency
The potential role of Tph-1 deficiency in immune tolerance
was studied in a model of skin allograft tolerance. Here mice
were treated with a tolerance-inducing regimen of DST in
combination with -CD40L on days 7, 5, and 3 and
then received an allogeneic CB6F1 (C57BL/6 × BALB/c)
skin graft on day 0 (Quezada et al., 2003). In the first experiments, the specific and irreversible inhibitor parachlorophenylalanine (PCPA), which has been reported to effectively
block the effects of Tph with multiple treatments (Côté et al.,
2003), was used. Approximately 90% of the PCPA-treated
mice receiving DST/-CD40L rejected their skin allografts
within 30 d. In contrast, 100% of DST/-CD40L–treated
WT mice retained their skin allografts for >50 d (Fig. 3 A).
The role of Tph-1 in allograft tolerance was then studied in
Tph-1/ mice (Fig. 3, A and B). It was shown that 80% of
the DST/-CD40L–treated Tph-1/ mice rejected their
skin grafts within 30 d as compared with DST/-CD40L–
treated WT mice (P < 0.0001 between these two groups by
log-rank test). Tph-1/ mice grafted with syngeneic grafts
retained those grafts as did WT controls, establishing that
Tph-1 is not involved in wound healing. Furthermore, allogeneic grafts placed on unmanipulated WT or Tph-1/
mice mounted similar rejection responses with regard to the
frequency and rates of graft rejection (Fig. 3 B). It was also
noted that the majority of MCs in Tph-1/ mice in donor
skin allografts were negative for Tph-1, indicating that they
were host derived (Fig. 3 C). The loss of tolerance in this
model was not caused by the absence of peripheral serotonin
synthesis in the Tph-1/ mice as adding back 5-hydroxytryptophan (5-HTP), which bypasses the Tph-1 deficiency to
restore serotonin levels, did not allow for long-lived tolerance in Tph-1/ mice (Fig. 3 B). Because MCs store serotonin
in their granules, reconstitution of serotonin biosynthesis
by 5-HTP administration in Tph-1/ mice was confirmed
by histological analysis of cytospins of peritoneal lavage
MCs (Fig. 3 D). It is therefore concluded that Tph-1 is required for the maintenance of peripheral tolerance independently of serotonin.
To determine whether rejection in the DST/-CD40L–
treated Tph-1/ mice was caused by the emergence of an
allogeneic T cell response,T cells from draining LNs 14 d after
the initial grafting were recalled with F1 antigen-presenting
cells to assess their cytokine production (Fig. 3 E). An increase
in the allogeneic-specific IFN- response (P = 0.0334) as
well as IL-17A response (P = 0.0084) was observed in the
DST/-CD40L–treated Tph-1/ mice compared with
similarly prepared WT mice.
Based on the finding that the highest signal of Tph-1 message and protein expression occurs in MCs, it was envisioned
that MC-derived Tph-1 is responsible for the phenotype seen
in the deficient mice. Wsh mice harbor a MC deficiency caused
by a c-Kit mutation and can be readily reconstituted with genetically deficient MCs to test the role of MC-derived genes
in immune responses (Grimbaldeston et al., 2005). As such,
2130

Wsh mice were reconstituted with WT or Tph-1/ BM-derived
MCs (BMMCs). As previously reported, DST/-CD40L–
treated Wsh mice reconstituted with WT BMMCs show a
gradual erosion of tolerance leading to rejection of 50%
of the allografts between days 30 and 60 after transplantation
(Lu et al., 2006). However, when DST/-CD40L–treated

Figure 4. Tph-1 is essential for the generation of protective
T cell–mediated antitumor immunity. (A) MB49 was inoculated, and
tumor growth was monitored over time in all the groups. One group
received 5-HTP every other day from the day before the start of experiment. Data show mean ± SEM of n = 6–8 mice/group and are representative of results from three independent experiments. P-values listed are for
the group they are shown next to in comparison with WT female mice
and were determined by two-way ANOVA. (B) On day 11 after tumor
inoculation, whole tumor draining LNs were isolated, plated, and restimulated with irradiated tumor to determine IFN- ELISPOTS after 18 h and
IL-17A ELISPOTS after 36 h, restimulated for 18 and 36 h, respectively.
Data show mean ± SEM for n = 10–16 mice/group and were pooled from
three independent experiments. The p-value shown was determined for
the indicated groups by Tukey posttest after one-way ANOVA analysis.
(C) MB49 was inoculated systemically through the tail vein in agematched female WT and Tph-1/ mice as well as female Wsh mice
systemically reconstituted with BMMCs from WT and Tph-1/ mice.
The graph is compiled from three independent experiments with total
numbers of mice indicated in the figure. The p-value was determined by
log-rank comparison between the two BMMC-reconstituted groups.
Tph-1 regulation of immunity | Nowak et al.
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Wsh mice were reconstituted with Tph-1/ BMMCs, it was
observed that all mice rejected their allograft within 30 d with
P = 0.0002 in comparison with WT BMMC-reconstituted
mice by log-rank test (Fig. 3 F). Therefore, it appears that
MC-derived Tph-1, and not Tph-1 produced by other cells,
is necessary for long-term graft tolerance.
Tph-1 and immune suppression to tumor
As MC expression of Tph-1 is critical for allograft tolerance
and MCs have been implicated in suppressing antitumor
immunity (Maltby et al., 2009), experiments were designed
to determine whether MC-derived Tph-1 mediated immune
tolerance to an intradermal (i.d.) skin tumor model. MB49
is a bladder cell carcinoma that expresses male minor histocompatibility antigen and readily grows and kills male mice
because they are centrally tolerant to H-Y (Summerhayes and
Franks, 1979; Halak et al., 1999). In contrast, female WT mice
have delayed tumor growth kinetics in comparison with WT
males yet nonetheless ultimately succumb to tumor. Strikingly,
female Tph-1/ mice have reduced tumor growth kinetics,
and 50% completely reject MB49. It was also confirmed
that the effect of Tph-1 deficiency was independent of serotonin biosynthesis by the lack of effect of administration of
5-HTP (Fig. 4 A). 11 d after tumor inoculation, tumor-specific
recall responses from T cells from the draining LNs were
measured (Fig. 4 B). Female Tph-1/ mice had significantly
higher numbers of IL-17A–specific spots (P < 0.01) in comparison with all other groups, and IFN-–specific spots were
elevated in female Tph-1/ mice although it did not reach
statistical significance. Through reconstitution of Wsh mice
with either BMMCs from either WT or Tph-1/ mice, it
was confirmed that Tph-1/ BMMCs conferred protection
to the same extent as female Tph-1/ mice with P = 0.0052
between WT and Tph-1/ BMMC-reconstituted mice
(Fig. 4 C). The data establish that MCs maintain a suppressive
antitumor microenvironment and that Tph-1 is a major
mediator within this context.

Tph-1 deficiency exacerbates experimental
autoimmune encephalomyelitis (EAE)
The question arose as to whether Tph-1 only enhances
immunity under immune-tolerant or -suppressive conditions,
or can it function in tempering inflammation in general? To
address this question, the impact of Tph-1 deficiency on a
central nervous system (CNS) inflammatory disease was studied.
EAE is a model of CNS inflammation in which encephalitogenic Th17 lineage T cells infiltrate the CNS, mediate damage, and cause ascending paralysis. Using suboptimal disease
conditions, it was found that Tph-1/ mice develop earlier
and more severe disease than controls (P = 0.0064; Fig. 5 A).
As seen in all other models tested, restoration of serotonin
levels by administration of 5-HTP had no effect on the immunological impact of Tph-1 deficiency. In this specific case,
it was shown that serotonin levels in serum were restored
to the same levels of controls after just one injection with
5-HTP (Fig. 5 B). Furthermore, long-term treatment of
5-HTP restored serotonin to a level greater than WT controls (P < 0.001; Fig. 5 C). The finding that serotonin is not
involved is also supported by the observation that serotonin
transporter–deficient mice have attenuated EAE (Hofstetter
et al., 2005).
Further characterization of immune responses during
EAE found that Tph-1/ mice have an enhanced frequency
of encephalitogenic T cells. Analysis of T cell responses during EAE revealed that on day 7 after immunization (when neither group showed disease), Tph-1/ mice had greater numbers
of CD4+ T cells expressing CCR6 (P = 0.0484), one of the
adhesion molecules necessary to be on the first wave of T cells
that infiltrate the CNS (Fig. 6 A; Liston et al., 2009; Reboldi
et al., 2009). Tph-1/ mice also had elevated recall IL-17A
production by CD4+ T cells (P = 0.0002). At late stages of
disease, Tph-1/ mice also had elevated numbers of CD4+
and CD8+ T cells that were infiltrating the CNS, which have
high IL-17A and IFN- recall responses (Fig. 6 B). To determine whether this effect is just caused by differences in T cell

Figure 5. Tph-1/ mice have exacerbated EAE independent of their serotonin
level. (A) WT, Tph-1/, and Tph-1/ + 5-HTP–
treated (starting on day 1 and continuing
every other day for the duration of the experiment) mice were monitored and scored. Data
are pooled from three independent experiments and show mean ± SEM for n = 13
mice/group. P-values indicate significance
in comparison with WT mice and were calculated by Mann–Whitney U test. (B) Serum
serotonin levels of WT, Tph-1/, and Tph-1/ +
5-HTP–treated (one shot 2 d prior) mice on
day 1 after EAE induction were determined by
ELISA (n = 11–12 mice/group pooled from
three independent experiments). (C) Serum
serotonin levels of WT, Tph-1/, and Tph-1/ + 5-HTP–treated (last shot given 2 d before sample collection) mice on day 21 after EAE induction were
determined by ELISA (n = 13 mice/group pooled from three independent experiments). The p-value was determined by one-way ANOVA analysis and indicates difference from WT mice. (B and C) Mean ± SEM is shown.
JEM Vol. 209, No. 11
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Figure 6. Tph-1/ mice have increased encephalitogenic T cell responses. (A) Day 7 after inoculation for EAE, mice were taken down and draining
LNs were stained for the indicated parameters (after restimulation for cytokine stains). Data are pooled from three independent experiments (n = 11
mice/group), and mean is indicated. (B) Day 21 after inoculation, lymphocytes from the CNS were isolated and stained for the indicated parameters
(after restimulation for cytokine stains). Data are pooled from three independent experiments (n = 15–18 mice/group), and mean is indicated.
(A and B) P-values were determined by Student’s t test. (C) Mice were injected with activated MOG35–55-specific T cells, and disease severity was monitored over time. Data are pooled from two independent experiments and show mean ± SEM for n = 14–16 mice/group. The p-value was determined by
Mann–Whitney U test. (D) Wsh mice were given WT or Tph-1/ BMMCs systemically and given 8 wk to reconstitute. These mice and age-matched controls were immunized for active EAE and monitored for disease severity over time. Data show mean ± SEM for n = 10–15 mice/group pooled from two
independent experiments.

priming, myelin-specific Th17 cells were adoptively transferred into WT and Tph-1/ mice. Data show that these
T cells could effectively initiate disease in Tph-1/ mice
but not controls (P < 0.0001), showing that Tph-1/ mice
are better able to sustain and facilitate encephalitogenic
T cell–mediated pathogenesis (Fig. 6 C). Although hampered
by differences in EAE severity caused by the increased age
of the mice, the phenotype of Wsh mice reconstituted with
Tph-1/ BMMCs looked consistent with that of Tph-1/
mice, suggesting MC-derived Tph-1 is responsible for this
effect (Fig. 6 D).
Tph-1/ mice have enhanced signaling
of mammalian target of rapamycin (mTOR)
The mTOR pathway can promote CD4 T cell differentiation
to Th1 and Th17 cells (Delgoffe et al., 2009), and its activity is inhibited in vitro with loss of essential amino acids
2132

(Cobbold et al., 2009). Therefore, it presented itself as a
potential target for mediating the differences observed in
WT and Tph-1/ mice. The phosphorylation of S6 riboprotein, one of the targets of mTOR, in CD4+ T cells was
measured in the draining LNs 4 d after EAE immunization,
and we found that it was elevated in Tph-1/ mice (P =
0.04; Fig. 7). This suggests that comparatively there is a
reduction of mTOR activity in WT mice that is consistent
with there potentially being a tryptophan-deficient micro
environment imposed by Tph-1.
DISCUSSION
The findings presented herein describe Tph-1 as an important and novel MC-derived regulator of immunological tolerance. This single molecule exerts striking alterations in
immunological outcomes in models of transplantation tolerance, tumor growth, and autoimmunity. Tph-1 metabolizes
Tph-1 regulation of immunity | Nowak et al.
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Figure 7. Tph-1/ mice have enhanced mTOR activity.
(A) Example staining of P-S6 and its isotype control antibody is
shown. (B) Day 4 after inoculation for EAE, mice were taken
down, draining LNs were harvested, and CD4+ T cells were stained
for P-S6 expression (and isotype control). Data are pooled from
three independent experiments with n = 15 mice/group. Mean is
indicated, and the p-value was determined by Student’s t test.

tryptophan for the purpose of producing serotonin. However, the experiments presented here clearly show that the
major immunological impact of this pathway is not through
the regulation of serotonin levels and therefore must be
caused by its ability to exhaust tryptophan as suggested by the
mTOR experiments.
There are several catabolic enzymes that have been suggested to contribute to the establishment of immune tolerance.
For example, during skin allograft tolerance, DCs activated
by regulatory T cells can express enzymes to consume 9 of the
10 essential amino acids and cause a reduction in mTOR signaling (Cobbold et al., 2009). Extensive work on IDO, one
of the tryptophan-catabolizing enzymes, also shows that it
can limit immune responses through the induction of the
GCN2 stress response, which promotes anergy, as well as the
production of tryptophan metabolites that suppress inflammation (Munn and Mellor, 2007). There are also some indications that different catabolic enzymes may counter-regulate
the activity of each other. For example, the production of nitric
oxide by inducible nitric oxide synthase can prevent IDO activity (Katz et al., 2008). However, in the case of Tph-1 expression by MCs, this does not appear to be occurring because
MCs have little to no messenger RNA expression for other
catabolic enzymes, so competition for substrate is not likely
contributing to the immunosuppressive activity of Tph-1.
In the case of Tph-1, the question arises as to which cell
type is the target of the tryptophan deficiency in the tolerant
microenvironment. Although we observe enhancement of
mTOR activity in CD4 T cells with Tph-1 deficiency during
EAE, it is not yet clear whether this is the case in our transplant and tumor models. In addition, there could be additional
targets of Tph-1 activity. For example, we have recently reported that within the tolerant allograft, graft-derived DCs
mediate regional allo-specific unresponsiveness. Upon analysis
of gene expression of these DCs, it appears that they have
experienced a nutrient-stressed environment (de Vries et al.,
2011). We would contend that this is caused by Tph-1 activities on DCs from the increased MCs that infiltrate the tolerant
allograft. It would also be of interest to determine the factors
that up-regulate Tph-1 expression in MCs as well as additional cell types to potentially mediate immune tolerance.
The experiments presented provide a new prospective
on this immunologically important enzyme. Its end product
serotonin can impact inflammation, particularly in the gut
JEM Vol. 209, No. 11

(O’Connell et al., 2006; Nakamura et al., 2008). It has
also been observed in Tph-1/ mice that there is an
enhanced ability to clear lymphocytic choriomeningitis
virus (Lang et al., 2008) and reject the MC-38 colon
cancer line (Nocito et al., 2008). However, in these cases,
this is dependent on the loss of serotonin in these mice.
Therefore, Tph-1 likely regulates immunity by regulating
serotonin levels or by exhausting tryptophan depending on
the nature of the immune response invoked. Certainly, the
fact that Tph-1 can so profoundly impact tolerance and inflammation provides compelling incentive to consider Tph-1
as a novel target in immune intervention.
MATERIALS AND METHODS
Mice. Tph-1/ mice fully backcrossed to a C57BL/6 background were
provided by N. Horseman (University of Cincinnati, Cincinnati, OH) and
maintained at the Dartmouth College animal facility. Male and female 6–8wk-old C57BL/6 mice were bred in-house for measurement of tryptophan
in serum, all EAE experiments, and all ELISPOT experiments. In all other
experiments, C57BL/6 mice were purchased from the National Cancer
Institute. 2D2 TCR transgenic mice were provided by V. Kuchroo (Harvard
University, Cambridge, MA) and maintained in-house. C57BL/6 KitW-sh
(Wsh) mice were purchased from the Jackson Laboratory. CB6F1 (C57BL/6 ×
BALB/c hybrid) were purchased from the National Cancer Institute. Experiments were performed under protocols approval by the Institutional Animal
Care and Use Committee of Dartmouth College, and mice were maintained
in a specific pathogen–free facility at Dartmouth Medical School.
MC reconstitution. BMMCs for MC reconstitution were generated by
culturing BM cells with 20 ng/ml IL-3 (PeproTech) and 50 ng/ml stem cell
factor (SCF; PeproTech) for 5–8 wk as shown previously (Lu et al., 2006).
Purity was assessed by anti-CD117 and anti-FCRI staining on BMMC
cultures (Lu et al., 2006). A total of 4–5 × 106 BMMCs were then injected
i.d., i.v., and i.p. into Wsh recipients. Mice were allowed to rest for 8–12 wk
before use in experiments. At the end of the experiment, reconstitution was
confirmed by flow cytometry or histology.
Skin grafting. Skin grafting was performed as previously described (Markees
et al., 1998). In brief, 1-cm2 full-thickness tail skins were collected from
CB6F1 allogeneic donor or C57BL/6 syngenic donor mice. Skins were then
stored on PBS-soaked gauze and were on the following day applied to the
dorsal surface of age-matched WT or Tph-1/ host mice. Indicated groups
were treated 7 d before grafting, via the i.v. injection of 3 × 107 DST in conjunction with an injection of 250 µg anti-CD40L (clone MR1), followed by
further injections on days 5 and 3 before graft. This regimen results in
long-term tolerization of the mice to alloantigen.
Cell culture, tumor challenge, and vaccination. Murine bladder carcinoma cell line MB49 was maintained in complete medium (RPMI 1640
containing 10% fetal calf serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamine, and 50 µM 2-mercaptoethanol). Mice were injected
with 2.5 × 105 MB49 tumor cells i.d. on the right flank, and tumor diameters
were measured with a caliper thrice weekly. Alternatively, mice were challenged with 2.5 × 105 MB49 tumor cells i.v. in the tail vein and were monitored for survival.
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EAE immunization and clinical evaluation. Age-matched WT and
Tph-1/ mice were immunized subcutaneously with 125 µg MOG35–55
peptide (Peptides International) emulsified in IFA (Sigma-Aldrich) supplemented with 0.5 mg/mouse Mycobacterium tuberculosis H37 (Difco Laboratories) on day 0 and an i.p. injection of 200 ng pertussis toxin (List Biologicals)
on days 0 and 2. For adoptive transfer EAE, donor 2D2 transgenic T cells
received a standard immunization as previously described (Nowak et al.,
2009), and lymphocytes were isolated out of mice 10 d later. Cells were
stimulated with 20 µg/ml MOG35–55, 10 µg/ml anti–IFN- (BioXCell),
20 ng/ml IL-23 (BD), 10 ng/ml IL-6 (PeproTech), and 10 ng/ml IL-1
(PeproTech) for 4 d before reisolation of live T cells (80% positive for
IL-17A). Recipient mice were injected with 1.0 × 106 T cells i.v. Mice were
scored as previously described (Becher et al., 2002).
Antibodies and reagents. Mouse monoclonal antibodies to CD8 (53-6.7)
and CD4 (GK1.5) were purchased from eBioscience. Mouse monoclonal
antibodies to CD4 (RMA4.5), CD45 (30-F11), IL-17A (TC11-18H10.1),
IFN- (XMG1.2), CCR6 (29-2L17), CD117 (ACK2), FCR1 (MAR-1),
CD11b (M1/70), CD11c (N418), F4/80 (BM8), and CD19 (6D5) were
purchased from BioLegend. Tph-1 antibody was purchased from Santa Cruz
Biotechnology, Inc. Secondary F(ab)2 anti–rabbit IgG antibody was purchased from eBioscience. P-S6 antibody and its isotype control antibody
were purchased from Cell Signaling Technology.
ELISPOT antibodies for IFN- were purchased from Mabtech and
those for IL-17A were purchased from BioLegend. Both were developed
using the AEC substrate kit from BD. ELISA kits for serotonin (Enzo Life
Sciences) and tryptophan (Rocky Mountain Diagnostics) were used according
to the manufacturers’ directions. 5-HTP (Sigma-Aldrich) and PCPA (SigmaAldrich) were given i.p. at 5.5 mg/mouse every other day in all indicated
experiments starting the day before any other treatment.
Histology. Sections were cut and stained as previously described (Lu et al.,
2006). In brief, tissues were fixed in OCT, sectioned onto slides, fixed with
methanol and acetone, stained with antibody in 10% serum, washed extensively, and mounted with Prolong Gold (Molecular Probes) according to the
manufacturer’s directions. Unstained and single-stain sections were performed
for each tissue. In addition, the same staining cocktails were used on tissue
from Tph-1/ mice to serve as a negative control for Tph-1 and serotonin
stains. Images were taken on an LSM 510 confocal microscope (Carl Zeiss)
and analyzed using LSM 5 Image Browser (Carl Zeiss).
Flow cytometry. Single cell suspensions were incubated with antibodies
conjugated with FITC, PE, PerCP, APC, Alexa Fluor 647, and/or Alexa
Fluor 700. Intracellular staining and restimulation for cytokine staining was
performed as previously described (Nowak et al., 2009). To stain for Tph-1,
cells were surface stained, washed, fixed with Fixation/Permeabilization
Buffer (BD), washed, permeabilized with Perm/Wash (BD), stained with
Tph-1 antibody, washed, stained with secondary antibody, washed, and
resuspended for analysis. For all staining steps, 10% normal rat serum was included. P-S6 staining was performed as follows: cells were blocked in 10%
serum, surface stained, washed, fixed with 4% paraformaldehyde, washed,
fixed and permeabilized with methanol, washed, blocked with 10% serum,
intracellularly stained, washed, and resuspended for analysis. Five-color analy
ses were performed on a modified FACScan (BD) running CellQuest software (BD) and Rainbow software (Cytek).
RNA preparation and qRT-PCR. All cell populations were sorted on a
FACS Aria (BD). For MC samples, the cell number acquired was insufficient for postsort analysis, so the samples were assessed for expression of
several MC markers and products to confirm specificity of cells. RNA was
prepared according to the manufacturer’s directions using an RNeasy
Mini kit (QIAGEN). MC samples were further amplified and converted
to cDNA using QuantiTect Whole Transcriptome kit (QIAGEN). All other
samples were transcribed to cDNA using the iScript cDNA synthesis kit
(Bio-Rad Laboratories). qRT-PCR was performed as previously described
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(Becher et al., 2002). All samples were standardized to expression of -actin.
Primers used are as follows: -actin (5-CCACACCCGCCAGTTCG-3
and 5-TCTGGGCCTCGTCACCCACAT-3), Tph-1 (5-GAAGAC
AACATCCCGCAACT-3 and 5-GTTCAGCCAAGAGAGGAACG-3),
arginase (5-CAGAAGAATGGAAGAGTCAG-3 and 5-CAGATATG
CAGGGAGTCACC-3), dopa decarboxylase (5-AGGGCAGAGAAAGAA
TGAAAGCA-3 and 5-GGAGTGGTAGTTATTTTTCTCTTTCCA-3),
histidine decarboxylase (5-GATCAGATTTCTACCTGTGG-3 and
5-GTGTACCATCATCCACTTGG-3), IDO (5-TGGCAAACTGGA
AGAAAAAG-3 and 5-ATTGCTTTCAGGTCTTGACG-3), inducible
nitric oxide synthase (5-ACCCCTGTGTTCCACCAGGAGATGTT-3 and
5-TGAAGCCATGACCTTTCGCATTAGCA-3), l-threonine dehydrog
enase (5-AAGCACGCGCCTGACTTC-3 and 5-CCGAGCATTG
CTGTCATCTAGA-3), TDO (5-TGGGAACTAGATTCTGTTCG-3 and
5-TCGCTGCTGAAGTAAGAGCT-3), and Tph-2 (5-CAGGAGAGGG
TTGTCCTTGG-3 and 5-TTTGCCGCTTTTCTTGTCCT-3).
Statistical analysis. Data graphs were made using Prism software (GraphPad
Software) and expressed as the mean ± SEM. Differences for graphs with
one grouping variables were analyzed by Student’s t test (two groups) or
one-way analysis of variance (ANOVA) and Tukey analysis (three or more
groups). Log-rank tests were used to compare skin graft survival and survival
of mice inoculated with MB49. For the study of MB49 growth kinetics,
two-way ANOVA was used to assess significance. In EAE time course experiments, statistical relevance was determined using Mann–Whitney U Test.
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